Literature DB >> 19943075

Administration of human immunoglobulin suppresses development of murine systemic vasculitis induced with Candida albicans water-soluble fraction: an animal model of Kawasaki disease.

Kei Takahashi1, Toshiaki Oharaseki, Yuki Yokouchi, Noriko N Miura, Naohito Ohno, Akiko I Okawara, Hisao Murata, Shiro Naoe, Kazuo Suzuki.   

Abstract

We investigated the inhibitory effect of human immunoglobulin (h-Ig) on the development of coronary arteritis in a murine model of vasculitis induced with a Candida albicans water-soluble fraction (CAWS). CAWS was intraperitoneally injected to C57BL/6 mice for 5 days. Then h-Ig was administered according to various schedules. The animals were sacrificed in week 5, and the status of vasculitis in the coronary arteries and the aortic root was investigated histologically. The groups in which h-Ig was administered for 5 days from day 3 and from day 5 of the experiment showed a significant reduction in the incidence of panvasculitis. In addition, the scope and severity of the inflammation of the aortic root and the coronary arteries were reduced in both groups. In the group administered h-Ig for 5 days from day 1 and the group administered a high dose of h-Ig once on day 1 or day 3, no suppression of development of vasculitis was observed. The h-Ig acted by suppressing the generation and progression of vasculitis in this CAWS-induced murine vasculitis model.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19943075     DOI: 10.1007/s10165-009-0250-5

Source DB:  PubMed          Journal:  Mod Rheumatol        ISSN: 1439-7595            Impact factor:   3.023


  6 in total

1.  Diagnostic potential of antibody titres against Candida cell wall β-glucan in Kawasaki disease.

Authors:  K Ishibashi; R Fukazawa; N N Miura; Y Adachi; S Ogawa; N Ohno
Journal:  Clin Exp Immunol       Date:  2014-07       Impact factor: 4.330

2.  Tropospheric winds from northeastern China carry the etiologic agent of Kawasaki disease from its source to Japan.

Authors:  Xavier Rodó; Roger Curcoll; Marguerite Robinson; Joan Ballester; Jane C Burns; Daniel R Cayan; W Ian Lipkin; Brent L Williams; Mara Couto-Rodriguez; Yosikazu Nakamura; Ritei Uehara; Hiroshi Tanimoto; Josep-Anton Morguí
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-19       Impact factor: 11.205

3.  Mizoribine provides effective treatment of sequential histological change of arteritis and reduction of inflammatory cytokines and chemokines in an animal model of Kawasaki disease.

Authors:  Kei Takahashi; Toshiaki Oharaseki; Tomokazu Nagao; Yuki Yokouchi; Hitomi Yamada; Noriko Nagi-Miura; Naohito Ohno; Tsutomu Saji; Tomio Okazaki; Kazuo Suzuki
Journal:  Pediatr Rheumatol Online J       Date:  2011-09-29       Impact factor: 3.054

Review 4.  Kawasaki disease: pathophysiology and insights from mouse models.

Authors:  Magali Noval Rivas; Moshe Arditi
Journal:  Nat Rev Rheumatol       Date:  2020-05-26       Impact factor: 20.543

5.  A novel mouse model of coronary stenosis mimicking Kawasaki disease induced by Lactobacillus casei cell wall extract.

Authors:  Eisuke Suganuma; Satoshi Sato; Satoko Honda; Atsuko Nakazawa
Journal:  Exp Anim       Date:  2020-01-13

6.  Etanercept suppresses arteritis in a murine model of kawasaki disease: a comparative study involving different biological agents.

Authors:  Ryuji Ohashi; Ryuji Fukazawa; Makoto Watanabe; Hanako Tajima; Noriko Nagi-Miura; Naohito Ohno; Shinichi Tsuchiya; Yuh Fukuda; Shunichi Ogawa; Yasuhiko Itoh
Journal:  Int J Vasc Med       Date:  2013-03-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.